Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV16/18 Infection

14 de noviembre de 2026 actualizado por: Beijing Xunsheng Biomedical Research Co., Ltd.

An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV Infection in Subjects Who Are Positive for HPV16/18

This study is an open-label, single-arm clinical trial designed to evaluate a therapeutic intervention for HPV infection in subjects who test positive for HPV16/18. The study aims to enroll 300 subjects. All participants must be confirmed as HPV16/18-positive via HPV genotyping nucleic acid testing during the screening phase. Subjects who meet all inclusion criteria will report to the study site on Day 0 and be assigned to a specific dosage group. Following the completion of eligibility assessments and baseline safety evaluations, subjects will receive an injection of the HPV-targeting nucleic acid therapeutic on Day 0, Day 21 (±3 days), and Day 42 (±3 days).

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

This study is an open-label, single-arm clinical trial designed to evaluate a therapeutic intervention for HPV infection in subjects who test positive for HPV16/18. The study aims to enroll 300 subjects. All subjects must be confirmed as HPV16/18-positive via HPV genotyping nucleic acid testing during the screening phase. The study is divided into two phases:

Phase 1: This phase includes two dosage groups-0.05 mg and 0.5 mg. Subjects will be assigned to one of these dosage groups according to pre-established allocation rules and will receive a dose on Day 0 (D0), Day 21 (D21), and Day 42 (D42). Subjects will undergo short-term follow-ups on Day 70 (D70) and Day 126 (D126), as well as long-term follow-ups approximately 6 months and 12 months after the third dose.

Phase 2: This phase consists of a 0.5 mg dosage group, with subjects receiving a dose on Day 0 (D0), Day 21 (D21), and Day 42 (D42). Subjects will undergo short-term follow-ups on Day 70 (D70) and Day 126 (D126), as well as long-term follow-ups approximately 6 months and 12 months after the third dose.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

300

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Hebei
      • Qinhuangdao, Hebei, Porcelana
        • Reclutamiento
        • Beidaihe Hospital of Qinhuangdao City
        • Contacto:
          • Yanqiu Zheng
          • Número de teléfono: +86 185 3358 8529
          • Correo electrónico: 18310917293@163.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 64 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  1. Participants must be aged 18-64 years (inclusive); only female participants will be enrolled.
  2. Subjects will voluntarily join the study and sign an informed consent form.
  3. During the screening period, there shall be no clinically significant abnormalities in medical history, physical examination, vital signs, 12-lead electrocardiogram, or clinical laboratory test results; the investigator will determine that the subject is suitable for enrollment.
  4. During the screening period, the HPV16/18 genotyping nucleic acid test result must be positive, and the subject must meet one of the following criteria: (1) a positive HPV16/18 test record during the screening period, with no current evidence of intraepithelial lesions; (2) a diagnosis of high-grade intraepithelial lesions of the cervix, vagina, or vulva confirmed by histopathological examination, with the subject meeting the enrollment criteria and treatment plan after specialist assessment; (3) the subject has previously undergone surgery or other local treatment for a related intraepithelial lesion, and the HPV16/18 test remains positive during the screening period, with no residual lesions currently present, or histopathological examination confirms the presence of residual or recurrent low-grade or high-grade intraepithelial lesions. (HPV subtype test results obtained within 30 days prior to administration, as well as TCT results and pathological biopsy results obtained within 90 days prior to administration, are acceptable).
  5. Fertile subjects (defined as females who have not undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, and whose menopause has occurred for ≥12 months) must agree to use highly effective contraceptive measures with their partner during the study treatment period and for at least 12 months after the final dose, including oral contraceptives, intrauterine devices, barrier contraception combined with spermicidal agents, or partner sterilization.
  6. Female subjects during the screening period must have negative serum or urine pregnancy tests and must not be in the lactation period. Be willing to undergo pregnancy testing during the screening period, before each dose administration, and at the end of the study.
  7. Be willing and able to comply with and complete all study procedures.

Exclusion Criteria:

  1. Presence of any skin condition on the upper arm that may interfere with the assessment of the injection-site reaction (ISR), including but not limited to extensive tattoos, scars, rashes, infections, or wounds.
  2. Presence of severe poor venous condition that precludes blood sample collection as required by the protocol.
  3. Presence, during screening, of an acute infection of the genital or anal region requiring systemic anti-infective therapy (excluding HPV infection).
  4. Pregnancy or lactation; or a history of miscarriage within the 3 months preceding screening.
  5. Any medical condition judged by the investigator to increase the risk of biopsy-related bleeding.
  6. In addition to the study indication, any clinically significant acute or chronic disease that, as judged by the investigator, may increase the risk of trial drug exposure or interfere with study evaluation.
  7. Inadequacy for adequate colposcopic evaluation.
  8. Presence of any of the following conditions: 1) Pathological confirmation of adenocarcinoma, adenocarcinoma in situ (AIS), or invasive carcinoma in the target lesion during the screening period; 2) A history of malignant tumors of the cervix, vagina, vulva, or anal region; 3) Colposcopic findings during the screening period suggesting a suspicious malignant tumor; 4) Having undergone total hysterectomy, thereby precluding assessment of cervical lesions (however, if the uterus was resected solely for benign lesions while the patient still has vulvar/vaginal/anal lesions, this does not automatically disqualify the subject); 5) Presence of any other uncurated malignant tumor in a site other than those described above within 5 years prior to enrollment (excluding cured papillary thyroid carcinoma, basal cell carcinoma of the skin, cervical carcinoma in situ, etc.).
  9. Screening: Use of immunosuppressants continuously (for more than 7 days) within the 30 days prior to screening, including but not limited to: glucocorticoids (excluding physiological replacement doses: prednisone ≤10 mg/d or other glucocorticoids at equivalent doses); cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, methotrexate, etc.
  10. Screening: Receipt of any medication known to have anti-HPV activity (including injectable HPV prophylactic vaccines) within the 30 days prior to screening.
  11. History of severe allergic reactions (requiring hospitalization), severe reactions to any medication or vaccine injection, or any known or suspected allergy to any component of the study drug or formulation.
  12. Presence of uncontrolled systemic chronic diseases.
  13. Laboratory tests during the screening period meeting any of the following criteria: 1) Hemoglobin <90 g/L; 2) Neutrophil count <1.0 × 10⁹/L; 3) Platelet count <80 × 10⁹/L; 4) AST or ALT> 1.5 × ULN; 5) Creatinine clearance <60 mL/min (using the Cockcroft-Gault formula); 6) International Normalized Ratio (INR)> 1.5 × ULN; 7) HIV antibody positive; 8) HCV antibody positive (and HCV RNA positive); 9) HBsAg positive (and HBV DNA positive); 10) Active syphilis (RPR/TPPA positive and requiring treatment).
  14. Any history of alcohol or drug abuse that the Investigator deems likely to affect subject safety or study adherence.
  15. Subjects that the Investigator deems unwilling or unable to adhere to the requirements of the study protocol.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: AVL-1100

Dosage and administration for the nucleic acid-based therapeutic injection for HPV infection: A total of 3 injections are to be administered, with an interval of three weeks between each dose. The product is to be administered via intramuscular injection into the lateral aspect of the upper arm, 2-3 finger-widths below the acromion; each dose should be administered into one of the upper arms. Following each injection, the subject must remain under observation for 60 minutes, during which time a safety assessment will be conducted. Provided no serious adverse events occur, the subject may proceed with the scheduled follow-up visits.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and tolerability
Periodo de tiempo: Up to Day 300

Dose-limiting toxicities (DLTs), as well as the incidence and severity of adverse events, etc.

Up to Day 300

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Effectiveness
Periodo de tiempo: Up to Day 300

The rate of HPV16/18 viral reversion to negativity at the final visit.

Up to Day 300
Effectiveness
Periodo de tiempo: Up to Day 300

The degree of lesion regression assessed by histopathological evaluation at the final visit.

Up to Day 300
Immunogenic
Periodo de tiempo: Up to Day 300

Cell-mediated antigen-specific immune response against HPV16/18.

Up to Day 300

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

21 de octubre de 2025

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

28 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • AVL-1100-01

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir